Limits...
Oral Administration of Gintonin Attenuates Cholinergic Impairments by Scopolamine, Amyloid-β Protein, and Mouse Model of Alzheimer's Disease.

Kim HJ, Shin EJ, Lee BH, Choi SH, Jung SW, Cho IH, Hwang SH, Kim JY, Han JS, Chung C, Jang CG, Rhim H, Kim HC, Nah SY - Mol. Cells (2015)

Bottom Line: The brains of AD patients show a reduction in acetylcholine concentration caused by cholinergic system impairments.In this study, we used gintonin to investigate the effect of LPA receptor activation on the cholinergic system in vitro and in vivo using wild-type and AD animal models.Furthermore, this study showed that gintonin could be a novel agent for the restoration of cholinergic system damages due to Aβ and could be utilized for AD prevention or therapy.

View Article: PubMed Central - PubMed

Affiliation: Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University, Seoul 143-701, Korea.

ABSTRACT
Gintonin is a novel ginseng-derived lysophosphatidic acid (LPA) receptor ligand. Oral administration of gintonin ameliorates learning and memory dysfunctions in Alzheimer's disease (AD) animal models. The brain cholinergic system plays a key role in cognitive functions. The brains of AD patients show a reduction in acetylcholine concentration caused by cholinergic system impairments. However, little is known about the role of LPA in the cholinergic system. In this study, we used gintonin to investigate the effect of LPA receptor activation on the cholinergic system in vitro and in vivo using wild-type and AD animal models. Gintonin induced [Ca(2+)]i transient in cultured mouse hippocampal neural progenitor cells (NPCs). Gintonin-mediated [Ca(2+)]i transients were linked to stimulation of acetylcholine release through LPA receptor activation. Oral administration of gintonin-enriched fraction (25, 50, or 100 mg/kg, 3 weeks) significantly attenuated scopolamine-induced memory impairment. Oral administration of gintonin (25 or 50 mg/kg, 2 weeks) also significantly attenuated amyloid-β protein (Aβ)-induced cholinergic dysfunctions, such as decreased acetylcholine concentration, decreased choline acetyltransferase (ChAT) activity and immunoreactivity, and increased acetylcholine esterase (AChE) activity. In a transgenic AD mouse model, long-term oral administration of gintonin (25 or 50 mg/kg, 3 months) also attenuated AD-related cholinergic impairments. In this study, we showed that activation of G protein-coupled LPA receptors by gintonin is coupled to the regulation of cholinergic functions. Furthermore, this study showed that gintonin could be a novel agent for the restoration of cholinergic system damages due to Aβ and could be utilized for AD prevention or therapy.

No MeSH data available.


Related in: MedlinePlus

Effect of gintonin (GT; 25 or 50 mg/kg, p.o.) on the decrease in ChAT-IR in the hippocampus of APPswe/PSEN-1 double Tg mice. Donepezil (DPZ; 1 mg/kg, i.p.) was used as a reference drug. Each value is the mean ± S.E.M for five mice. *P < 0.05, **P < 0.01 vs. Saline-treated non-Tg mice, #P < 0.05, ##P < 0.01 vs. Saline-treated APPswe/PSEN-1 double Tg mice (one-way ANOVA followed by Fisher’s PLSD test). Scale bar = 200 μm.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4588723&req=5

f6-molce-38-9-796: Effect of gintonin (GT; 25 or 50 mg/kg, p.o.) on the decrease in ChAT-IR in the hippocampus of APPswe/PSEN-1 double Tg mice. Donepezil (DPZ; 1 mg/kg, i.p.) was used as a reference drug. Each value is the mean ± S.E.M for five mice. *P < 0.05, **P < 0.01 vs. Saline-treated non-Tg mice, #P < 0.05, ##P < 0.01 vs. Saline-treated APPswe/PSEN-1 double Tg mice (one-way ANOVA followed by Fisher’s PLSD test). Scale bar = 200 μm.

Mentions: Accumulating evidences showed that dystrophy and reorganization of cholinergic terminals are observed in the hippocampus and cortex of APPswe/PSEN-1 double Tg mice without significant change in cholinergic neuronal bodies of basal fore-brain system, including medial septum and nucleus basalis (Jaffar et al., 2001; Perez et al., 2007; Wong et al., 1999). In these studies, cholinergic axonal dystrophy in the hippocampus could be observed as early as 2–3 months of age, that is prior to the formation of amyloid deposition, while there was no significant change in cholinergic neuronal bodies in the medial septum and nucleus basalis of 10–16-month-old APPswe/PSEN-1 double Tg mice with extensive amyloid deposition. Thus, we have focused on the changes in ChAT-IR in the hippocampus. Hippocampal ChAT-IR was significantly lower in the APPswe/PSEN-1 double Tg mice than that in the non-Tg mice (CA1 and CA3: **P < 0.01 vs. non-Tg mice treated with saline; DG: *P < 0.05 vs. non-Tg mice treated with saline) (Fig. 6, upper panel). Long-term treatment with gintonin (25 or 50 mg/kg, p.o., thrice a week for 3 months) significantly increased hippocampal ChAT-IR [CA1 and CA3: 25 or 50 mg/kg gintonin vs. Saline, ##P < 0.01; DG: 50 mg/kg gintonin vs. Saline, #P < 0.05] in the APPswe/PSEN-1 double Tg mice, and these effects were comparable to those of donepezil (1 mg/kg) (Fig. 6, lower panel). These results are consistent with the results above-mentioned biochemical analyses on gintonin-mediated protection of cholinergic systems in the APPswe/PSEN-1 double Tg mice.


Oral Administration of Gintonin Attenuates Cholinergic Impairments by Scopolamine, Amyloid-β Protein, and Mouse Model of Alzheimer's Disease.

Kim HJ, Shin EJ, Lee BH, Choi SH, Jung SW, Cho IH, Hwang SH, Kim JY, Han JS, Chung C, Jang CG, Rhim H, Kim HC, Nah SY - Mol. Cells (2015)

Effect of gintonin (GT; 25 or 50 mg/kg, p.o.) on the decrease in ChAT-IR in the hippocampus of APPswe/PSEN-1 double Tg mice. Donepezil (DPZ; 1 mg/kg, i.p.) was used as a reference drug. Each value is the mean ± S.E.M for five mice. *P < 0.05, **P < 0.01 vs. Saline-treated non-Tg mice, #P < 0.05, ##P < 0.01 vs. Saline-treated APPswe/PSEN-1 double Tg mice (one-way ANOVA followed by Fisher’s PLSD test). Scale bar = 200 μm.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4588723&req=5

f6-molce-38-9-796: Effect of gintonin (GT; 25 or 50 mg/kg, p.o.) on the decrease in ChAT-IR in the hippocampus of APPswe/PSEN-1 double Tg mice. Donepezil (DPZ; 1 mg/kg, i.p.) was used as a reference drug. Each value is the mean ± S.E.M for five mice. *P < 0.05, **P < 0.01 vs. Saline-treated non-Tg mice, #P < 0.05, ##P < 0.01 vs. Saline-treated APPswe/PSEN-1 double Tg mice (one-way ANOVA followed by Fisher’s PLSD test). Scale bar = 200 μm.
Mentions: Accumulating evidences showed that dystrophy and reorganization of cholinergic terminals are observed in the hippocampus and cortex of APPswe/PSEN-1 double Tg mice without significant change in cholinergic neuronal bodies of basal fore-brain system, including medial septum and nucleus basalis (Jaffar et al., 2001; Perez et al., 2007; Wong et al., 1999). In these studies, cholinergic axonal dystrophy in the hippocampus could be observed as early as 2–3 months of age, that is prior to the formation of amyloid deposition, while there was no significant change in cholinergic neuronal bodies in the medial septum and nucleus basalis of 10–16-month-old APPswe/PSEN-1 double Tg mice with extensive amyloid deposition. Thus, we have focused on the changes in ChAT-IR in the hippocampus. Hippocampal ChAT-IR was significantly lower in the APPswe/PSEN-1 double Tg mice than that in the non-Tg mice (CA1 and CA3: **P < 0.01 vs. non-Tg mice treated with saline; DG: *P < 0.05 vs. non-Tg mice treated with saline) (Fig. 6, upper panel). Long-term treatment with gintonin (25 or 50 mg/kg, p.o., thrice a week for 3 months) significantly increased hippocampal ChAT-IR [CA1 and CA3: 25 or 50 mg/kg gintonin vs. Saline, ##P < 0.01; DG: 50 mg/kg gintonin vs. Saline, #P < 0.05] in the APPswe/PSEN-1 double Tg mice, and these effects were comparable to those of donepezil (1 mg/kg) (Fig. 6, lower panel). These results are consistent with the results above-mentioned biochemical analyses on gintonin-mediated protection of cholinergic systems in the APPswe/PSEN-1 double Tg mice.

Bottom Line: The brains of AD patients show a reduction in acetylcholine concentration caused by cholinergic system impairments.In this study, we used gintonin to investigate the effect of LPA receptor activation on the cholinergic system in vitro and in vivo using wild-type and AD animal models.Furthermore, this study showed that gintonin could be a novel agent for the restoration of cholinergic system damages due to Aβ and could be utilized for AD prevention or therapy.

View Article: PubMed Central - PubMed

Affiliation: Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University, Seoul 143-701, Korea.

ABSTRACT
Gintonin is a novel ginseng-derived lysophosphatidic acid (LPA) receptor ligand. Oral administration of gintonin ameliorates learning and memory dysfunctions in Alzheimer's disease (AD) animal models. The brain cholinergic system plays a key role in cognitive functions. The brains of AD patients show a reduction in acetylcholine concentration caused by cholinergic system impairments. However, little is known about the role of LPA in the cholinergic system. In this study, we used gintonin to investigate the effect of LPA receptor activation on the cholinergic system in vitro and in vivo using wild-type and AD animal models. Gintonin induced [Ca(2+)]i transient in cultured mouse hippocampal neural progenitor cells (NPCs). Gintonin-mediated [Ca(2+)]i transients were linked to stimulation of acetylcholine release through LPA receptor activation. Oral administration of gintonin-enriched fraction (25, 50, or 100 mg/kg, 3 weeks) significantly attenuated scopolamine-induced memory impairment. Oral administration of gintonin (25 or 50 mg/kg, 2 weeks) also significantly attenuated amyloid-β protein (Aβ)-induced cholinergic dysfunctions, such as decreased acetylcholine concentration, decreased choline acetyltransferase (ChAT) activity and immunoreactivity, and increased acetylcholine esterase (AChE) activity. In a transgenic AD mouse model, long-term oral administration of gintonin (25 or 50 mg/kg, 3 months) also attenuated AD-related cholinergic impairments. In this study, we showed that activation of G protein-coupled LPA receptors by gintonin is coupled to the regulation of cholinergic functions. Furthermore, this study showed that gintonin could be a novel agent for the restoration of cholinergic system damages due to Aβ and could be utilized for AD prevention or therapy.

No MeSH data available.


Related in: MedlinePlus